Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$0.60
$0.60
$0.48
▼
$25.44
$1.23M1.4122,322 shsN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$1.42
-0.7%		$1.54
$0.58
▼
$2.50
$4.70M0.961.03 million shs59,500 shs
LianBio stock logo
LIAN
LianBio
$0.03
-20.4%		$0.08
$0.27
▼
$4.99
$3.43M0.231.04 million shs18,800 shs
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
$2.57
-0.4%		$4.86
$2.46
▼
$15.15
$4.08M0.71204,451 shs48,614 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
-2.05%-2.05%-16.37%-16.86%-37.28%
LianBio stock logo
LIAN
LianBio
0.00%+13.71%-23.46%-63.88%-30.18%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-2.64%-15.96%-42.28%-58.15%-72.74%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$0.60
$0.60
$0.48
▼
$25.44
$1.23M1.4122,322 shsN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$1.42
-0.7%		$1.54
$0.58
▼
$2.50
$4.70M0.961.03 million shs59,500 shs
LianBio stock logo
LIAN
LianBio
$0.03
-20.4%		$0.08
$0.27
▼
$4.99
$3.43M0.231.04 million shs18,800 shs
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
$2.57
-0.4%		$4.86
$2.46
▼
$15.15
$4.08M0.71204,451 shs48,614 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
-2.05%-2.05%-16.37%-16.86%-37.28%
LianBio stock logo
LIAN
LianBio
0.00%+13.71%-23.46%-63.88%-30.18%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-2.64%-15.96%-42.28%-58.15%-72.74%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00
N/AN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
1.00
SellN/AN/A
LianBio stock logo
LIAN
LianBio
0.00
N/AN/AN/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest ASLN, SILO, INM, and LIAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/21/2026
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/1/2026
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/24/2026
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/11/2026
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
5/27/2026
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$12M0.10N/AN/A($6.50) per share-0.09
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$4.94M0.95N/AN/A$6.71 per share0.21
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/A$2.71 per shareN/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
$54.08K75.47N/AN/A$7.10 per share0.36
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
-$44.22M-$21.92N/AN/AN/AN/A-8,454.87%-121.60%N/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
-$8.16M-$2.89N/AN/AN/A-132.87%-80.85%-68.11%9/23/2026 (Estimated)
LianBio stock logo
LIAN
LianBio
-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-$4.23M-$4.36N/AN/AN/A-6,726.39%-81.75%-66.35%9/2/2026 (Estimated)

Latest ASLN, SILO, INM, and LIAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/2/2026N/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-$0.32N/AN/AN/A$0.02 millionN/A
8/13/2026Q2 2026
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-$0.32-$0.76-$0.44-$0.76$0.02 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/AN/AN/AN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/AN/AN/AN/AN/A
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/AN/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/A
1.05
1.05
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/A
3.12
3.12
LianBio stock logo
LIAN
LianBio
N/A
10.06
10.06
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
N/A
5.36
5.36

Institutional Ownership

CompanyInstitutional Ownership
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
58.82%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
20.12%
LianBio stock logo
LIAN
LianBio
74.85%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
5.58%

Insider Ownership

CompanyInsider Ownership
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
4.69%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.85%
LianBio stock logo
LIAN
LianBio
7.59%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
3.63%
CompanyEmployeesShares OutstandingFree FloatOptionable
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
302.04 million1.95 millionNo Data
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
103.31 million3.29 millionNot Optionable
LianBio stock logo
LIAN
LianBio
110108.06 million99.86 millionNot Optionable
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
21.59 million1.53 millionNot Optionable

Recent News About These Companies

Silo Pharma’s lead asset SPC-15, an intranasal 5-HT4 receptor agonist targeting post-traumatic stress disorder receives Canadian patent
August 20, 2026  |  pharmabiz.comP
Silo Pharma Gets Canadian Patent Allowance for Stress Disorder Treatment
August 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/silo-pharma-gets-canadian-patent-204920200.html
Silo Pharma Acquires Digital Assets via Stock Issuance
August 19, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/silo-pharma-acquires-digital-assets-via-stock-issuance?utm_source=marketbeat.com&utm_medium=referral
Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment
August 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/18/3347240/0/en/silo-pharma-receives-notice-of-allowance-for-canadian-patent-application-for-novel-ptsd-treatment.html
Silo Pharma Granted European Patent Covering Novel PTSD Therapy
August 10, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/silo-pharma-granted-european-patent-covering-novel-ptsd-therapy-1036435534
Silo Pharma Announces European Patent Grant for SPC-15 PTSD Prevention Therapy
August 10, 2026  |  quiverquant.comQ
Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform
August 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/06/3340312/0/en/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform.html
Silo Pharma Advances QwikAgents Commercial Launch and SPC-15 Development
July 21, 2026  |  quiverquant.comQ
Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330474/0/en/silo-pharma-advances-growth-platforms-for-ai-agent-commercialization-and-lead-ptsd-drug-program.html
Is Silo Pharma, Inc. (SILO) Stock an AI Opportunity After NVIDIA Partnership Boosts QwikAgents Platform?
July 15, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/is-silo-pharma-inc-silo-stock-an-ai-opportunity-after-nvidia-partnership-boosts-qwikagents-platform-1801641/
Silo Pharma’s QwikAgents joins AMD AI developer program to advance AI agent platform
July 14, 2026  |  msn.comhttps://www.msn.com/en-us/technology/software/silo-pharma-s-qwikagents-joins-amd-ai-developer-program-to-advance-ai-agent-platform/ar-AA27UgLT
Silo Pharma Unit Eyes Faster AI Agent Development Through AMD Partnership
July 14, 2026  |  benzinga.comhttps://www.benzinga.com/news/health-care/26/07/60447743/silo-pharma-unit-eyes-faster-ai-agent-development-through-amd-partnership?utm_source=snapi
Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform
July 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/14/3326873/0/en/silo-pharma-s-qwikagents-joins-amd-ai-developer-program-to-advance-enterprise-ai-agent-platform.html
CCC Intelligent Solutions, Circle rise premarket; Silo Pharma, Fermi America fall
July 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/ccc-intelligent-solutions-circle-rise-125702837.html
Silo Pharma Sinks on Stock Sale
July 10, 2026  |  baystreet.cahttps://www.baystreet.ca/stockstowatch/23630/Silo-Pharma-Sinks-on-Stock-Sale
Silo Pharma shares slide after announcing up to $11.7 million private placement (SILO)
July 10, 2026  |  msn.comhttps://www.msn.com/en-us/travel/news/silo-pharma-shares-slide-after-announcing-up-to-117-million-private-placement-silo/ar-AA27Essb
Silo Pharma Announces $4 Million Private Placement with Up to Approximately $7.7 Million in Potential Additional Gross Proceeds from Warrants
July 10, 2026  |  quiverquant.comQ
Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
July 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/10/3325447/0/en/silo-pharma-announces-up-to-11-7-million-private-placement-priced-at-the-market-under-nasdaq-rules.html
Certara, Silo Pharma Advance AI Agent Strategies with Nvidia Initiatives
July 7, 2026  |  benzinga.comhttps://www.benzinga.com/news/health-care/26/07/60316675/certara-silo-pharma-advance-ai-agent-strategies-with-nvidia-initiatives?utm_source=snapi
Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program
July 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/07/3323157/0/en/silo-pharma-subsidiary-qwikagents-set-to-advance-enterprise-ai-agent-platform-through-nvidia-developer-program.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AMD logo on a glowing processor chip with red circuit traces, highlighting AI and data-center semiconductor demand.
AMD’s AI Bubble Could Burst Into Explosive Upside
By Thomas Hughes | July 27, 2026
SpaceX logo beside a rocket on a launch pad at sunset, with a colorful sky in the background.
SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
By Jeffrey Neal Johnson | August 3, 2026
Laboratory with a cryogenic quantum processor chamber, optical laser setup on a table, and data monitors displaying waveforms.
Quantum Earnings Week: Winners and Losers Are Finally Emerging
By Nathan Reiff | August 8, 2026
SoundHound AI logo displayed within a glowing orange ring against a dark background with light wave effects.
SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
By Thomas Hughes | August 10, 2026
Interior hallway of an AMC movie theater with illuminated AMC logo, film posters, and showtime screens for numbered auditoriums.
Paramount’s 30-Film Promise Puts AMC Back in the Box Office Conversation
By Jeffrey Neal Johnson | August 12, 2026
ASLAN Pharmaceuticals stock logo

ASLAN Pharmaceuticals NASDAQ:ASLN

$0.60 0.00 (0.00%)
As of 08/24/2026

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

InMed Pharmaceuticals stock logo

InMed Pharmaceuticals NASDAQ:INM

$1.42 -0.01 (-0.70%)
As of 01:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

LianBio stock logo

LianBio NASDAQ:LIAN

$0.03 -0.01 (-20.35%)
As of 08/24/2026

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Silo Pharma stock logo

Silo Pharma NASDAQ:SILO

$2.57 -0.01 (-0.39%)
As of 01:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas